Celtaxsys planning Phase III program for CF candidate

Celtaxsys Inc. (Atlanta, Ga.) said it hopes to start Phase III testing in 2H19 evaluating acebilustat (CTX-4430) to treat cystic fibrosis after reporting data from the Phase II EMPIRE-CF trial of the candidate in the indication.

While the leukotriene A4 hydrolase (LTA4H) inhibitor

Read the full 423 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE